The global xanthoma market is expected to reach USD 8.0 billion by 2023, and the market is projected to grow at a CAGR of ~ 6.0 % during the forecast period 2017-2023. Xanthoma is a dermatology condition characterized by fatty growth underneath the skin. There may be clusters of growths in the same area or several individual growths on different parts of the body. The exact causes of xanthoma is unknown, however, genetic factors have been indicated a cause of this conditions such as cogenosis type 1a, autosomal recessive hypercholesterolemia, alagille syndrome, and cholesterol storage disease. Get Free Sample Copy at https://www.marketresearchfuture.com/sample_request/4860 Market Competitive Some of the key players profiled in the report are AstraZeneca PLC GlaxoSmithKline PLC Johnson & Johnson Bayer HealthCare Pharmaceuticals LLC Pfizer Inc. Novartis International AG Teva pharmaceutical industries Novo Nord...